StemCell Therapy

The 41 rating InvestorsObserver gives to Tyme Technologies Inc (TYME) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 33 percent of stocks in the Biotechnology industry, TYMEs 41 overall rating means the stock scores better than 41 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 41 would rank higher than 41 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Tyme Technologies Inc (TYME) stock has fallen -5.26% while the S&P 500 has gained 0.33% as of 2:25 PM on Friday, Aug 28. TYME is down -$0.06 from the previous closing price of $1.14 on volume of 1,253,542 shares. Over the past year the S&P 500 is up 19.54% while TYME is down -6.90%. TYME lost -$0.23 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Read this article:
Is Tyme Technologies Inc (TYME) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

This entry was posted on August 28, 2020 at 11:55 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |